These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1238 related articles for article (PubMed ID: 24240112)

  • 21. DNA repair mutations and outcomes in ovarian cancer--letter.
    Soslow RA
    Clin Cancer Res; 2015 Feb; 21(3):658. PubMed ID: 25646181
    [No Abstract]   [Full Text] [Related]  

  • 22. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
    Coleman RL; Sill MW; Bell-McGuinn K; Aghajanian C; Gray HJ; Tewari KS; Rubin SC; Rutherford TJ; Chan JK; Chen A; Swisher EM
    Gynecol Oncol; 2015 Jun; 137(3):386-91. PubMed ID: 25818403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
    Sugino K; Tamura R; Nakaoka H; Yachida N; Yamaguchi M; Mori Y; Yamawaki K; Suda K; Ishiguro T; Adachi S; Isobe M; Yamaguchi M; Kashima K; Motoyama T; Inoue I; Yoshihara K; Enomoto T
    Sci Rep; 2019 Nov; 9(1):17808. PubMed ID: 31780705
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
    Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
    Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inherited mutations in fallopian tube, ovarian and primary peritoneal carcinoma: Changes in diagnoses and mutational frequency over 20 years.
    Weiss AS; Swisher E; Pennington KP; Radke M; Khasnavis N; Garcia RL; Kilgore MR; Lee MK; Norquist BM
    Gynecol Oncol; 2020 Oct; 159(1):214-220. PubMed ID: 32709535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
    Harter P; Johnson T; Berton-Rigaud D; Park SY; Friedlander M; Del Campo JM; Shimada M; Forget F; Mirza MR; Colombo N; Zamagni C; Chan JK; Imhof M; Herzog TJ; O'Donnell D; Heitz F; King K; Stinnett S; Barrett C; Jobanputra M; Xu CF; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):443-9. PubMed ID: 26740259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
    Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
    Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
    Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ
    Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian cancer: Status of homologous recombination pathway as a predictor of drug response.
    De Picciotto N; Cacheux W; Roth A; Chappuis PO; Labidi-Galy SI
    Crit Rev Oncol Hematol; 2016 May; 101():50-9. PubMed ID: 26964893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study.
    Piek JM; Torrenga B; Hermsen B; Verheijen RH; Zweemer RP; Gille JJ; Kenemans P; van Diest PJ; Menko FH
    Fam Cancer; 2003; 2(2):73-8. PubMed ID: 14574155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenotypic heterogeneity of hereditary gynecologic cancers: a report from the Creighton hereditary cancer registry.
    Casey MJ; Bewtra C; Lynch HT; Snyder C; Stacy M; Watson P
    Fam Cancer; 2013 Dec; 12(4):719-40. PubMed ID: 23666231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
    Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
    da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
    BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of somatic mutations in BRCA2 BRC domain with chemotherapy sensitivity and survival in high grade serous ovarian cancer.
    Zhang G; Zhang J; Zhu Y; Liu H; Shi Y; Mi K; Li M; Zhao Q; Huang Z; Huang J
    Exp Cell Res; 2021 Sep; 406(1):112742. PubMed ID: 34302857
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
    Kummar S; Oza AM; Fleming GF; Sullivan DM; Gandara DR; Naughton MJ; Villalona-Calero MA; Morgan RJ; Szabo PM; Youn A; Chen AP; Ji J; Allen DE; Lih CJ; Mehaffey MG; Walsh WD; McGregor PM; Steinberg SM; Williams PM; Kinders RJ; Conley BA; Simon RM; Doroshow JH
    Clin Cancer Res; 2015 Apr; 21(7):1574-82. PubMed ID: 25589624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic characterization of early onset ovarian carcinoma.
    Bernards SS; Norquist BM; Harrell MI; Agnew KJ; Lee MK; Walsh T; Swisher EM
    Gynecol Oncol; 2016 Feb; 140(2):221-5. PubMed ID: 26718727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    Park W; Chen J; Chou JF; Varghese AM; Yu KH; Wong W; Capanu M; Balachandran V; McIntyre CA; El Dika I; Khalil DN; Harding JJ; Ghalehsari N; McKinnell Z; Chalasani SB; Makarov V; Selenica P; Pei X; Lecomte N; Kelsen DP; Abou-Alfa GK; Robson ME; Zhang L; Berger MF; Schultz N; Chan TA; Powell SN; Reis-Filho JS; Iacobuzio-Donahue CA; Riaz N; O'Reilly EM
    Clin Cancer Res; 2020 Jul; 26(13):3239-3247. PubMed ID: 32444418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas.
    Galic V; Willner J; Wollan M; Garg R; Garcia R; Goff BA; Gray HJ; Swisher EM
    Genes Chromosomes Cancer; 2007 Mar; 46(3):239-47. PubMed ID: 17171684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 mutations in Japanese patients with ovarian, fallopian tube, and primary peritoneal cancer.
    Sakamoto I; Hirotsu Y; Nakagomi H; Ouchi H; Ikegami A; Teramoto K; Amemiya K; Mochizuki H; Omata M
    Cancer; 2016 Jan; 122(1):84-90. PubMed ID: 26439132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 62.